View in EDS HTML Full Text PDF Full Text

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib.

Saved in:

Bibliographic Details
Title:	A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib.
Authors:	Matsumura, Yuki¹ (AUTHOR) yukimatsumura1980@gmail.com, Inomata, Sho¹ (AUTHOR), Yamaguchi, Hikaru¹ (AUTHOR), Mine, Hayato¹ (AUTHOR), Takagi, Hironori¹ (AUTHOR), Watanabe, Masayuki¹ (AUTHOR), Ozaki, Yuki¹ (AUTHOR), Yamaura, Takumi¹ (AUTHOR), Fukuhara, Mitsuro¹ (AUTHOR), Muto, Satoshi¹ (AUTHOR), Okabe, Naoyuki¹ (AUTHOR), Hasegawa, Takeo¹ (AUTHOR), Shio, Yutaka¹ (AUTHOR), Suzuki, Hiroyuki¹ (AUTHOR)
Source:	Thoracic Cancer. Aug2021, Vol. 12 Issue 15, p2225-2228. 4p.
Database:	Academic Search Ultimate
Full text is not displayed to guests. Login for full access.

Be the first to leave a comment!